Robert T. Abraham
Research Subjects
Robert T. Abraham has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Christina H. Eng
Oncology Research Unit, Pfizer Worldwide Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, USA
3 shared publicationsFang Wang
Oncology R&D Group, Pfizer Worldwide Research and Development, 401 N. Middletown Road, Pearl River, NY 10965, USA
2 shared publicationsJeremy Myers
Oncology R&D Group, Pfizer Worldwide Research and Development, 401 N. Middletown Road, Pearl River, NY 10965, USA
2 shared publicationsNaval P. Shanware
Oncology Research Unit, Pfizer Worldwide Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, USA
2 shared publicationsAndreas Giannakou
Oncology R&D Group, Pfizer Worldwide Research and Development, 401 N. Middletown Road, Pearl River, NY 10965, USA
1 shared publicationAndrew R. Mullen
University of Texas–Southwestern Medical Center at Dallas
1 shared publication
Latest Publications
- 10 January 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 367 (6474) , 146-147
A sugary input to leucine sensing
Glucose channels the amino acid leucine into synthetic versus degradative pathways
- 10 January 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 367 (6474) , 146-147
A sugary input to leucine sensing
Glucose channels the amino acid leucine into synthetic versus degradative pathways
- Open Access
- 1 June 2017
- Published by Elsevier in Cell Reports
- Vol. 19 (13) , 2665-2680
Purine Nucleotide Availability Regulates mTORC1 Activity through the Rheb GTPase
- 1 June 2017
- Published by Elsevier in Cell Reports
- Vol. 19 (13) , 2665-2680
Open AccessPurine Nucleotide Availability Regulates mTORC1 Activity through the Rheb GTPase
- 1 March 2017
- Published by Elsevier in Molecular Cell
- Vol. 65 (6) , 959-960
The Pten-Parkin Axis: At the Nexus of Cancer and Neurodegeneration
- 1 March 2017
- Published by Elsevier in Molecular Cell
- Vol. 65 (6) , 959-960
The Pten-Parkin Axis: At the Nexus of Cancer and Neurodegeneration
- 31 May 2016
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 9 (430) , fs10
4E-BP2 hardwires lymphocytes for rapamycin sensitivity
A study reveals why lymphocytes are so sensitive to the immunosuppressant rapamycin.
- 31 May 2016
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 9 (430) , fs10
4E-BP2 hardwires lymphocytes for rapamycin sensitivity
A study reveals why lymphocytes are so sensitive to the immunosuppressant rapamycin.
- 1 March 2016
- Published by Elsevier in Cell Metabolism
- Vol. 23 (3) , 397-398
Toward a Molecular Definition of Leucine-Dependent mTORC1 Activation
- 1 March 2016
- Published by Elsevier in Cell Metabolism
- Vol. 23 (3) , 397-398
Toward a Molecular Definition of Leucine-Dependent mTORC1 Activation
- 30 June 2015
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 21 (13) , 2905-2910
Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer Treatment
Cancer cells bypass normal controls over mitotic cell-cycle progression to achieve a deregulated state of proliferation. The retinoblastoma tumor suppressor protein (pRb) governs a key cell-cycle checkpoint that normally prevents G1-phase cells from entering S-phase in the absence of appropriate mitogenic signals. Cancer cells frequently overcome pRb-dependent growth suppression via constitutive phosphorylation and inactivation of pRb function by cyclin-dependent kinase (CDK) 4 or CDK6 partnered with D-type cyclins. Three selective CDK4/6 inhibitors, palbociclib (Ibrance; Pfizer), ribociclib (Novartis), and abemaciclib (Lilly), are in various stages of development in a variety of pRb-positive tumor types, including breast cancer, melanoma, liposarcoma, and non–small cell lung cancer. The emerging, positive clinical data obtained to date finally validate the two decades-old hypothesis that the cyclin D–CDK4/6 pathway is a rational target for cancer therapy. Clin Cancer Res; 21(13); 2905–10. ©2015 AACR.
- 30 June 2015
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 21 (13) , 2905-2910
Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer Treatment
Cancer cells bypass normal controls over mitotic cell-cycle progression to achieve a deregulated state of proliferation. The retinoblastoma tumor suppressor protein (pRb) governs a key cell-cycle checkpoint that normally prevents G1-phase cells from entering S-phase in the absence of appropriate mitogenic signals. Cancer cells frequently overcome pRb-dependent growth suppression via constitutive phosphorylation and inactivation of pRb function by cyclin-dependent kinase (CDK) 4 or CDK6 partnered with D-type cyclins. Three selective CDK4/6 inhibitors, palbociclib (Ibrance; Pfizer), ribociclib (Novartis), and abemaciclib (Lilly), are in various stages of development in a variety of pRb-positive tumor types, including breast cancer, melanoma, liposarcoma, and non–small cell lung cancer. The emerging, positive clinical data obtained to date finally validate the two decades-old hypothesis that the cyclin D–CDK4/6 pathway is a rational target for cancer therapy. Clin Cancer Res; 21(13); 2905–10. ©2015 AACR.
- 9 January 2015
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 347 (6218) , 128-129
Making sense of amino acid sensing
Biochemically and spatially diverse intracellular mechanisms couple the activity of a cell growth regulatory complex to the availability of amino acids [Also see Reports by Wang et al. and Jewell et al. ]
- 9 January 2015
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 347 (6218) , 128-129
Making sense of amino acid sensing
Biochemically and spatially diverse intracellular mechanisms couple the activity of a cell growth regulatory complex to the availability of amino acids [Also see Reports by Wang et al. and Jewell et al. ]
- Open Access
- 25 September 2014
- Published by Springer Nature in Nature Communications
- Vol. 5 (1) , 4900
Glutamine deprivation stimulates mTOR-JNK-dependent chemokine secretion
The non-essential amino acid, glutamine, exerts pleiotropic effects on cell metabolism, signalling and stress resistance. Here we demonstrate that short-term glutamine restriction triggers an endoplasmic reticulum (ER) stress response that leads to production of the pro-inflammatory chemokine, interleukin-8 (IL-8). Glutamine deprivation-induced ER stress triggers colocalization of autophagosomes, lysosomes and the Golgi into a subcellular structure whose integrity is essential for IL-8 secretion. The stimulatory effect of glutamine restriction on IL-8 production is attributable to depletion of tricarboxylic acid cycle intermediates. The protein kinase, mTOR, is also colocalized with the lysosomal membrane clusters induced by glutamine deprivation, and inhibition of mTORC1 activity abolishes both endomembrane reorganization and IL-8 secretion. Activated mTORC1 elicits IL8 gene expression via the activation of an IRE1-JNK signalling cascade. Treatment of cells with a glutaminase inhibitor phenocopies glutamine restriction, suggesting that these results will be relevant to the clinical development of glutamine metabolism inhibitors as anticancer agents.
- 25 September 2014
- Published by Springer Nature in Nature Communications
- Vol. 5 (1) , 4900
Open AccessGlutamine deprivation stimulates mTOR-JNK-dependent chemokine secretion
The non-essential amino acid, glutamine, exerts pleiotropic effects on cell metabolism, signalling and stress resistance. Here we demonstrate that short-term glutamine restriction triggers an endoplasmic reticulum (ER) stress response that leads to production of the pro-inflammatory chemokine, interleukin-8 (IL-8). Glutamine deprivation-induced ER stress triggers colocalization of autophagosomes, lysosomes and the Golgi into a subcellular structure whose integrity is essential for IL-8 secretion. The stimulatory effect of glutamine restriction on IL-8 production is attributable to depletion of tricarboxylic acid cycle intermediates. The protein kinase, mTOR, is also colocalized with the lysosomal membrane clusters induced by glutamine deprivation, and inhibition of mTORC1 activity abolishes both endomembrane reorganization and IL-8 secretion. Activated mTORC1 elicits IL8 gene expression via the activation of an IRE1-JNK signalling cascade. Treatment of cells with a glutaminase inhibitor phenocopies glutamine restriction, suggesting that these results will be relevant to the clinical development of glutamine metabolism inhibitors as anticancer agents.
- 1 July 2014
- Published by Elsevier in Cell Metabolism
- Vol. 20 (1) , 4-6
Too Little mTORC1 Activity Injures the Liver
- 1 July 2014
- Published by Elsevier in Cell Metabolism
- Vol. 20 (1) , 4-6
Too Little mTORC1 Activity Injures the Liver
- 25 March 2013
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 30 (5) , 625-639
The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
Covering: up to the end of 2012 The Antibody Drug Conjugate (ADC) is a therapeutic modality consisting of a monoclonal antibody attached to a cytotoxic, small-molecule payload. The antibody portion of the ADC serves as a transport vehicle that recognizes and binds to a protein antigen expressed in tumor tissues. The localized delivery and release of the payload within or near malignant cells allows for targeted delivery of a potent cytotoxic agent to diseased tissue, while reducing damage to antigen-negative, normal tissues. Recent years have witnessed an explosive increase in ADC-based therapies, due mainly to clinical reports of activity in both hematologic and epithelial cancers. Accompanying this upsurge in ADC development is a renewed interest in natural product cytotoxins, which are typically highly potent cell-killing agents, but suffer from poor drug-like properties and narrow safety margins when systemically administered as conventional chemotherapeutics. In this review, we discuss recent advances related to the construction of ADCs, the optimization of ADC safety and efficacy, and the increasingly pivotal roles of natural product payloads in the current and future landscape of ADC therapy.
- 25 March 2013
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 30 (5) , 625-639
The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
Covering: up to the end of 2012 The Antibody Drug Conjugate (ADC) is a therapeutic modality consisting of a monoclonal antibody attached to a cytotoxic, small-molecule payload. The antibody portion of the ADC serves as a transport vehicle that recognizes and binds to a protein antigen expressed in tumor tissues. The localized delivery and release of the payload within or near malignant cells allows for targeted delivery of a potent cytotoxic agent to diseased tissue, while reducing damage to antigen-negative, normal tissues. Recent years have witnessed an explosive increase in ADC-based therapies, due mainly to clinical reports of activity in both hematologic and epithelial cancers. Accompanying this upsurge in ADC development is a renewed interest in natural product cytotoxins, which are typically highly potent cell-killing agents, but suffer from poor drug-like properties and narrow safety margins when systemically administered as conventional chemotherapeutics. In this review, we discuss recent advances related to the construction of ADCs, the optimization of ADC safety and efficacy, and the increasingly pivotal roles of natural product payloads in the current and future landscape of ADC therapy.